Emollient foam in topical drug delivery

Expert Opinion on Drug Delivery

Volumn 3, Issue 6, 2006, Pages 799-807

  Tamarkin, Dov ^a   Friedman, Doron ^a   Shemer, Avner ^b  

^a Foamix Ltd   (Israel)

^b Sanz Laniado Medical Center   (Israel)

Author keywords

Emollient foam; Skin penetration; Topical therapy; Usability

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; ATOPICLAIR; ATOPIFOAM; BETAMETHASONE VALERATE; BETTAMOUSSE; CLINDAMYCIN PHOSPHATE; CLOBETASOL PROPIONATE; CORTICOSTEROID; DERMATOLOGICAL AGENT; DRUG SOLVENT; DRUG VEHICLE; EMOLLIENT AGENT; EXCIPIENT; FELBINAC; FULL MARKS; GELLING AGENT; HYDROCORTISONE; HYDROCORTISONE ACETATE; LUXIQ; METRONIDAZOLE; MILICE; NONIONIC SURFACTANT; NONSTEROID ANTIINFLAMMATORY AGENT; PERFOAM; PERMETHRIN; PHENOTHRIN; PRAMOCAINE; PROCTOFOAM; PROPELLANT; RETINOID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER OIL CREAM;

ABSENCE OF SIDE EFFECTS; ACNE; ATOPIC DERMATITIS; CHEMICAL COMPOSITION; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CREAM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG QUALITY; DRUG SAFETY; DRUG SOLUBILITY; DRY SKIN; DYSKERATOSIS; EMULSION; FOAM; FOAM STABILITY; HUMAN; HYDRATION; LIPID SOLUBILITY; OINTMENT; PAIN; PATIENT COMPLIANCE; PEDICULOSIS; PERMEABILITY BARRIER; PHYSICAL CHEMISTRY; PSORIASIS; REVIEW; ROSACEA; SHELF LIFE; SKIN DISEASE; SKIN INFLAMMATION; SKIN IRRITATION; SKIN PENETRATION; SKIN PRURITUS; TEMPERATURE SENSITIVITY; WRINKLE; XERODERMA; XEROSIS;

ADMINISTRATION, TOPICAL; ANIMALS; DRUG CARRIERS; EMOLLIENTS; EMULSIONS; HUMANS; MARKETING;

EID: 33751225645     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.6.799     Document Type: Review

References (10)

1. WOODFORD R, BARRY BW: Bioavailability and activity of topical corticosteroids from a novel drug delivery system, the aerosol quick-break foam. J. Pharm. Sci. (1977) 66(1):99-103.
2. PARRINI M, CABITZA P, ARRIGO A, VANASIA M: Efficacy and tolerability of ketoprofen lysine salt foam for topical use in the treatment of traumatic pathologies of the locomotor apparatus. Clin. Ter. (1992) 141(9):199-204.
3. DAFFONCHIO L, BESTETTI A, CLAVENNA G, FEDELE G, FERRARI MP, OMINI C: Effects of a new foam formulation of ketoprofen lysine salt in experimental models of inflammation and hyperalgesia. Arzneimittelforschung (1995) 45(5):590-594.
4. PURDON CH, HAIGH JM, SURBER C, SMITH EW: Foam drug delivery in dermatology: beyond the scalp. Am. J. Drug Deliv. (2003)1(1):71-75.
5. HUANG X, TANOJO H, LENN J, DENG CH, KROCHMAL L: A novel foam vehicle for delivery of topical corticosteroids. J. Am. Acad. Dermatol. (2005) 53(1 Suppl. 1):S26-S38.
6. SHALITA AR, MYERS JA, KROCHMAL L, YAROSHINSKY A: The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J. Drugs Dermatol. (2005) 4(1):48-56.
7. NOLA I, KOSTOVIC K, KOTRULJA L, LUGOVIC L: The use of emollients as sophisticated therapy in dermatology. Acta Dermatovenerol. Croat. (2003) 11:80-87.
8. LODEN M, ACO HUD AB. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am. J. Clin. Dermatol. (2003) 4:771-788.
9. COUNCIL OF EUROPE: European Pharmacopoeia 5th edn. (2005):604-605.
10. GRAY J: New treatment options on the horizon for lice. Infect. Dis. Child. (2005) 18(10):32.